

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 April 2006 (27.04.2006)

PCT

(10) International Publication Number
WO 2006/045037 A3

(51) International Patent Classification:

A61K 49/00 (2006.01) A61K 38/00 (2006.01)
A01N 61/00 (2006.01) G01N 33/00 (2006.01)
A01N 37/18 (2006.01) A01K 67/00 (2006.01)
A61K 31/00 (2006.01) A01K 67/033 (2006.01)

(21) International Application Number:

PCT/US2005/037875

(22) International Filing Date: 19 October 2005 (19.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/969,335 19 October 2004 (19.10.2004) US
11/194,115 29 July 2005 (29.07.2005) US

(71) Applicant (for all designated States except US): ELAN
PHARMACEUTICALS, INC. [US/US]; 800 Gateway
Boulevard, South San Francisco, California 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHILCOTE,
Tamie, J. [US/US]; 187 Magellan Avenue, San Francisco,
California 94116 (US). GOLDSTEIN, Jason [US/US];
1420 El Camino Real #1, Burlingame, California 94010
(US). ANDERSON, John, P. [US/US]; 1323-A Lyon
Street, San Francisco, California 94115 (US). WALKER,
Donald [US/US]; 33 Mozden Lane, Pleasant Hill, CA
94523 (US).

(74) Agents: LIEBESCHUETZ, Joe et al.; TOWNSEND
AND TOWNSEND AND CREW LLP, Two Embarcadero
Center, 8th Floor, San Francisco, California 94111-3834
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY,
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
21 September 2006

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRUNCATED FRAGMENTS OF ALPHA-SYNUCLEIN IN LEWY BODY DISEASE

(57) Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and trans-
genic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated
C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as
determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus
of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synu-
clein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery,
diagnostics, therapeutics, and transgenic animals.

WO 2006/045037 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/37875

A. CLASSIFICATION OF SUBJECT MATTER

IPC: A61K 49/00(2006.01);A01N 61/00(2006.01),37/18(2006.01);A61K 31/00(2006.01),38/00(2006.01);G01N 33/00(2006.01);A01K 67/00(2006.01),67/033(2006.01)

USPC: 424/9.1;514/1,2;800/3,9,12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.1; 514/1,2; 800/3,9,12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TSIM, K.W. et al., Monoclonal antibodies specific for the different subunits of asymmetric acetylcholinesterase from chick muscle. J. Neurochem. July 1988, Vol. 51, No. 1, pages 95-104, see abstract	52
X	HAMBURGER, A.W., et al., Isolation and characterization of monoclonal antibodies reactive with endothelial cells. Tissue Cell. 1985, Vol. 17, No. 4, pages 451-459, abstract	52
X	US 6,780,971 B2 (Wolozin et al) 24 August 2004 (24.08.2004), column 17, lines 53-62	1, 4
A	TAKAHASHI, M. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neuroscience Letters. 2003, Vol. 336, pages 155-158.	1-52



Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 June 2006 (07.06.2006)

Date of mailing of the international search report

20 JUL 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Ram Shukla, Ph.D.

Telephone No. (571) 272-1600

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/37875

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	OKOCHI, M. Constitutive Phosphorylation of the Parkinson's Disease Associated alpha-Synuclein. The Journal of Biological Chemistry. January 2000, Vol 275. No. 1, pages 390-397.	1-52
A	KIM, T.D. et al. Structural Changes in alpha-Synuclein Affect its Chaperone-like Activity In Vitro. Protein Science. 2000, Vol 9. pages 2489-2496	1-52
A	HOYER, W. et al., Dependence of alpha-Synuclein Aggregate Morphology on Solution Conditions. J. Mol. Biol. 2002, Vol 322, pages 383-393.	1-52

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/37875

Continuation of B. FIELDS SEARCHED Item 3:
Google, EAST, STN
search terms: alpha-synuclein, phosphorylated, 1-115, 1-133, 1-135, 12C6, 7G8